Lassa fever

Coyle, Amanda L.

doi:10.1097/01.nurse.0000482873.70955.7b

Cited by 6 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study findings were also supported by those of Coyle (2016) [11] that access to diagnostic laboratory existed, hence selfdiagnosis, which led to misdiagnosis and culminated in their being treated for malaria, instead of Lassa fever disease.…”

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

Lived Experiences of Lassa Fever Survivors in Southsouth Nigeria

2022

Int J Nurs Health Care Res

View full text Add to dashboard Cite

Lassa fever, a viral disease, was first isolated in the late 1960s and affects 300,000 to 500.000 people, causing 5000, to 10,000 fatalities annually across West Africa. Although there are studies on the causes and prevalence of Lassa fever, there is a paucity of studies regarding the Quality of Life (QoL) and lived experiences of survivors, limiting the ability of governments to adequately meet their needs. The purpose of this study was to describe the Quality of Life (QoL) and lived experiences of Lassa fever survivors in the Southsouth region of Nigeria. Fifteen survivors of Lassa disease were interviewed. Findings revealed seven areas of concerns: culture care and therapeutic communication, emotional support, physical symptoms, social activities, and work productivity. Findings are useful for health care providers

show abstract

Section: Discussionsupporting

confidence: 87%

“…The high mortality is due to misdiagnosis of early symptoms of Lassa fever: fever, loss of appetite, and weakness, are similar to malaria disease. Lassa fever is a global public health problem and one of the emerging infectious diseases and with scanty information available such as diagnosis, treatments, vaccinations, and control [3].…”

Section: Introductionmentioning

confidence: 99%

Lived Experiences of Lassa Fever Survivors in Southsouth Nigeria

2022

Int J Nurs Health Care Res

View full text Add to dashboard Cite

show abstract

“…The last 3 years have seen Nigeria responding to year-round outbreaks of Lassa fever, especially during the 'Lassa fever season', a term that is often used to describe the yearly December-May upsurge in the number of cases. 1 Most cases of the disease in West Africa occur in Nigeria, and the 2019/2020 outbreak in the country holds the highest record for Lassa fever cases globally. Despite its discovery in 1969, Lassa fever research and response in the country have not gained adequate traction due to a number of health system challenges, such as the level 4 biosafety facility requirement for viral research, geographical confinement of the pathogen mostly within the West African subregion and the lack of approved therapeutics for the disease even after five decades of its discovery.…”

Section: Lassa Fever As a Stepping Stonementioning

confidence: 99%

“…NCDC coordinates the country’s response to disease outbreaks. The last 3 years have seen Nigeria responding to year-round outbreaks of Lassa fever, especially during the ‘Lassa fever season’, a term that is often used to describe the yearly December–May upsurge in the number of cases 1. Most cases of the disease in West Africa occur in Nigeria, and the 2019/2020 outbreak in the country holds the highest record for Lassa fever cases globally.…”

Section: Lassa Fever As a Stepping Stonementioning

confidence: 99%

Adapting public health response through lessons learnt: Nigeria’s experience from Lassa fever and COVID-19

et al. 2022

View full text Add to dashboard Cite

Response to public health emergencies requires continued adaptation and innovation. The Nigeria Centre for Disease Control (NCDC) is the country’s public health institute with the mandate to protect the health of Nigerians. Achieving such mandate in resource-limited settings with divergent demographic characteristics of the citizens, necessitates the readiness to learn from experience and to develop policies and activities in line with lessons learnt and best practices. This practice paper describes the initiatives of the NCDC towards adapting its public health response activities by establishing learning systems across its structure. The paper informs on some of the steps taken by the Centre regarding learning from the Lassa fever outbreak and the COVID-19 pandemic in Nigeria. It concludes that commitment and investments are key requirements for learning and adapting public health responses to achieve success with combating infectious diseases.

show abstract

“…LASV infection of humans occurs mostly by contact of mucosal surfaces with dust or food from tainted rodent urine or faeces [ 2 ]. While human-to-human transmission is uncommon it can occur after contact with infected body fluids [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates

Woolsey,

Cross,

Prasad

et al. 2024

Emerging Microbes & Infections

View full text Add to dashboard Cite

Lassa virus (LASV) is a World Health Organization (WHO) priority pathogen that causes high morbidity and mortality. Recently, we showed that a combination of three broadly neutralizing human monoclonal antibodies known as Arevirumab-3 (8.9F, 12.1F, 37.2D) based on the lineage IV Josiah strain protected 100% of cynomolgus macaques against heterologous challenge with lineage II and III strains of LASV when therapy was initiated beginning at day 8 after challenge. LASV strains from Benin and Togo represent a new lineage VII that are more genetically diverse from lineage IV than strains from lineages II and III. Here, we tested the ability of Arevirumab-3 to protect macaques against a LASV lineage VII Togo isolate when treatment was administered beginning 8 days after exposure. Unexpectedly, only 40% of treated animals survived challenge. In a subsequent study we showed that Arevirumab-3 protected 100% of macaques from lethal challenge when treatment was initiated 7 days after LASV Togo exposure. Based on our transcriptomics data, successful Arevirumab-3 treatment correlated with diminished neutrophil signatures and the predicted development of T cell responses. As the in vitro antiviral activity of Arevirumab-3 against LASV Togo was equivalent to lineage II and III strains, the reduced protection in macaques against Togo likely reflects the faster disease course of LASV Togo in macaques than other strains. This data causes concern regarding the ability of heterologous vaccines and treatments to provide cross protection against lineage VII LASV isolates.

show abstract

Lassa fever

Cited by 6 publications

References 6 publications

Lived Experiences of Lassa Fever Survivors in Southsouth Nigeria

Lived Experiences of Lassa Fever Survivors in Southsouth Nigeria

Adapting public health response through lessons learnt: Nigeria’s experience from Lassa fever and COVID-19

Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates

Contact Info

Product

Resources

About